The investment brings Ezra's total funding to $41 million, and will be used to accelerate the company's expansion to 20 cities and 50 locations across North America in 2024, as well as advance the use of its AI technology by leading imaging centers and clinicians. Ezra leverages FDA-cleared AI technology to reduce the time it takes to complete an MRI scan. By deploying its AIs at leading imaging centers, Ezra offers consumers the ability to access full-body MRI scanning at much more affordable pricing, and supports imaging centers in increasing throughput, efficiency, and affordability.

The round was co-led by Healthier Capital, a venture capital firm focused on applying innovative technology to healthcare and led by Amir Dan Rubin, former CEO of Amazon's One Medical. FirstMark Capital co-led the round, with participation from Allianz Life Ventures (the venture capital arm of Allianz Life Insurance Company of North America), the Schwarzman family, former Chairman of England's National Health Service (NHS) Lord David Prior, Gaingels, Republic, and Mana Ventures. Existing investors Credo Ventures, Seedcamp, LDV Capital, Accomplice, Founders Future, Vlad Tenev, Anne Wojcicki, and Esther Dyson also participated. Amir Dan Rubin will also join Ezra's Board of Directors.

Ezra is a healthcare AI company utilizing medical imaging and artificial intelligence to provide individuals with an innovative full body cancer screening service that is fast, accurate, and affordable. Founded in 2018 by Emi Gal, Ezra monitors for possible cancer and 500+ conditions in up to 13 organs, giving individuals the ability to detect potential cancer and other diseases at an earlier stage through preventative, proactive, and ongoing cancer screening via the company's Full Body MRI scan. By advocating for early cancer detection as part of annual health screenings, Ezra is on a mission to create a new standard of preventative care, providing people with the necessary knowledge to make decisions about their health.